Abstract
The Glucagon-like peptide 1 receptor (GLP-1R) is a well-established target for the treatment of type 2 diabetes and GLP-1R agonist-based therapies represent an effective approach which results in several GLP-1 analog drugs. However, the development of nonpeptidic agonist drugs targeting GLP-1R remains unsuccessful. A promising strategy aims to develop orally bioavailable, small-molecule positive allosteric modulators of GLP1-1R. Taking advantage of the recently reported cryo-EM structure of GLP-1R at its active state, we have performed structure-based screening studies which include potential allosteric binding site prediction and in silico screening of drug-like compounds, and conducted in vitro testing and site-specific mutagenesis studies. One compound with low molecular weight was confirmed as a positive allosteric modulator of GLP-1R as it enhances GLP-1′s affinity and efficacy to human GLP-1R in a dose dependent manner. This compound also stimulates insulin secretion synergistically with GLP-1. With the molecular weight of 399, this compound represents one of the smallest known GLP-1R PAMs, and demonstrates other favorable drug-like properties. Site-specific mutagenesis studies confirmed that the binding site of this compound partially overlaps with that of a known antagonist in the transmembrane domain. These results demonstrate that structure-based approach is useful for discovering nonpeptidic allosteric modulators of GLP-1R and the compound reported here is valuable for further drug development.
Similar content being viewed by others
References
Koole C et al (2013) Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function. Biochem. Soc. Trans. 41:172–179
Prasad-Reddy L, Isaacs D (2015) A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context 4:212283
Jazayeri A et al (2017) Crystal structure of the GLP-1 receptor bound to a peptide agonist. Nature 546:254–258
Zhang Y et al (2017) Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature 546:248–253
Song G et al (2017) Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators. Nature 546:312–315
Liang YL et al (2018) Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex. Nature 555:121–125
Knudsen LB et al (2007) Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc. Natl. Acad. Sci. USA 104:937–942
Chen D et al (2007) A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc. Natl. Acad. Sci. USA 104:943–948
Sloop KW (2010) Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 59:3099–3107
Wootten D et al (2011) Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids. J. Pharmacol. Exp. Ther. 336:540–550
Willard FS, Bueno AB, Sloop KW (2012) Small molecule drug discovery at the glucagon-like peptide-1 receptor. Exp. Diabetes Res. 2012:709893
Morris LC et al (2014) Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-py rrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). J. Med. Chem. 57:10192–10197
Hollenstein K et al (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499:438–443
May LT, Leach K, Sexton PM, Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47:1–51
Conn PJ, Christopoulos A, Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8:41–54
Khoury E, Clement S, Laporte SA (2014) Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics. Front. Endocrinol. 5:68
Bueno AB (2016) Positive allosteric modulation of the glucagon-like peptide-1 receptor by diverse electrophiles. J. Biol. Chem. 291:10700–10715
Redij T et al (2019) Structural modeling and in silico screening of potential small molecule allosteric agonists of glucagon-like peptide 1 receptor. ACS Omega 4:961–970
Irwin JJ, Shoichet BK (2005) ZINC—a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45:177–182
Halgren TA et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47(7), 1750–1759.
Repasky MP et al (2012) Docking performance of the glide program as evaluated on the Astex and DUD datasets: a complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide. J. Comput. Aided Mol. Des. 26:787–799
Wang R, Fu Y, Lai L (1997) A new atom-additive method for calculating partition coefficients. J. Chem. Inf. Comput. Sci. 37:615–621
Lastya A, Saraswati MR, Suastika K (2014) The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus. BMC Res. Notes 7(1):849
King AB, Armstrong DU, Chinnapongse S (2003) Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes. Diabetes Care 26:245–246
Toft-Nielsen MB, Madsbad S, Holst JJ (2001) Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J. Clin. Endocrinol. Metab. 86:3853–3860
Knop FK et al (2007) Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 56:1951–1959
Kjems LL, Holst JJ, Volund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380–386
Wootten D et al (2017) Allostery and biased agonism at class B G protein-coupled receptors. Chem. Rev. 117:111–138
Pupo AS et al (2016) Recent updates on GPCR biased agonism. Pharmacol. Res. 112:49–57
Atwood BK et al (2011) Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics 12:14
de Graaf C et al (2011) Structure-based discovery of allosteric modulators of two related class B G-protein-coupled receptors. ChemMedChem 6:2159–2169
Acknowledgements
We thank Dr. Raymond C. Stevens at ShanghaiTech University for sharing with us plasmids of human GLP-1R mutants S352A, V332W and T355A. The first two mutants were used in this work. We thank Dr. James A. McKee for helping prepare Fig. 1 and the figure of the chemical structure of compound C-1. Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR001878. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was supported in part by the Institute for Translational Medicine and Therapeutics' (ITMAT) Transdisciplinary Program in Translational Medicine and Therapeutics at University of Pennsylvania.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Redij, T., Ma, J., Li, Z. et al. Discovery of a potential positive allosteric modulator of glucagon-like peptide 1 receptor through virtual screening and experimental study. J Comput Aided Mol Des 33, 973–981 (2019). https://doi.org/10.1007/s10822-019-00254-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-019-00254-4